Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.
Phosphorex's director of nucleic delivery presents on Nanoparticles for the delivery of ASO to the CNS
Partnership Opportunities in Drug Delivery (PODD) conference explores the value of drug delivery technologies both to patients and pharma with a focus on the future direction of the field.
Our team presents the process of Nanosuspension for the novel Indirubin, for the potential treatment of Glioblastoma.
In collaboration with Brown University, Phosphorex presents on the use the nanoparticle formulation, to enable Systematic Delivery of Tx Agent to treat GBM
Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.
Following the recent growth capital investment from Ampersand Capital Partners, Phosphorex announced today the appointment of Jarlath Keating as Chief Executive Officer.
Phosphorex, a drug delivery-focused contract development and manufacturing organization providing microspheres and polymer and lipid nanoparticles, today announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the health
ONdrugDelivery article to discuss how automation of Lipid Nanoparticles production can benefit the development and manufacture of RNA-based drugs and vaccines.
Phosphorex & Dolomite experts share their insights about the most important considerations when making liposomes and lipid nanoparticles (LNPs) with microfluidics.
Phosphorex Presents Its Nanosuspension Formulation at Controlled Release Society Annual Meeting
Partnership Creates A Powerful Platform for Pharmaceutical Company Clients.
Phosphorex announced today the acquisition of new laboratory and office space in Hopkinton, MA to meet the increasing demand for its products and services.
AstraZeneca Highlights Collaboration with Phosphorex on use of Zetafinity® Technology to More Effectively Target Immune Cells